

ULTRALIFE CORP  
Form 8-K  
February 13, 2009  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

Current Report  
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

February 12, 2009

ULTRALIFE CORPORATION  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation or organization)

0-20852                      16-1387013  
(Commission File Number)    (I.R.S. Employer Identification No.)

2000 Technology Parkway, Newark, New York 14513  
(Address of principal executive offices)              (Zip Code)

(315) 332-7100  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Edgar Filing: ULTRALIFE CORP - Form 8-K

Item 2.02. Results of Operations and Financial Condition.

Ultralife Corporation (the "Company") reported revenue of \$49.2 million for the quarter ended December 31, 2008, an increase of \$12.4 million, or 34%, over the \$36.8 million in revenue reported for the fourth quarter of 2007. The company reported an operating loss of \$0.3 million in the fourth quarter of 2008, compared with an operating loss of \$2.7 million in the same period a year ago. The Company's press release is attached as Exhibit 99.1 to this Form 8-K.

In conjunction with its program to repurchase up to \$10 million worth of its own common stock, the company has spent approximately \$1.8 million through December 31, 2008 to acquire approximately 200,000 shares at an average price of roughly \$8.50 per share.

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Item 9.01. Financial Statements, Pro Forma Financials and Exhibits.

(a) Exhibits.

99.1 Press Release dated February 12, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ULTRALIFE CORPORATION

Dated: February 12, 2009. By: /s/ Robert W. Fishback

Vice President of Finance & CFO

---

INDEX TO EXHIBITS

(99) Additional Exhibits

99.1 Press Release dated February 12, 2009.